Eraxis
(Anidulafungin)ApprovedSmall molecule
Anidulafungin is used to treat serious fungal infections, particularly in the bloodstream and other parts of the body. It works by stopping the growth of certain types of fungi that can cause life-threatening infections, especially in hospitalized patients with weakened immune systems.[2] Eraxis is currently approved and in use across 12 indications[4].[1]
Eraxis is one of 298 small molecule programs targeting Peritonitis. It is currently in Approved.
12
Indications
23
Total Trials
0
Active Trials
297
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Eraxis
VVicuron Pharmaceuticals
Approved
Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Aspergillosis4 trials
Candidiasis4 trials
Candidemia2 trials
Infection1 trial
Antimicrobial PK in Infants With Suspected or Confirmed Infection
Completed·—··NCT00491426·450 enrolled
10 more indications
Liver Transplant1 trial
Transplant Recipient1 trial
Intravenous Administration1 trial
Critically Ill Patients1 trial
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment
Terminated·—·Phase 2·NCT00934934·61 enrolled
Liver Disease1 trial
Immunocompromised1 trial
Regulatory
FDA Approval Timeline[5]
Feb 17, 2006
ERAXIS
NDA NDA021632
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eraxis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Anidulafungin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 1,3-Beta-Glucan Synthase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- VVicuron Pharmaceuticals